UBS Cuts Price Target on Intuit (INTU) Following 4Q15 Results

Wedbush Cuts Price Target on Intuit (INTU) Following 4Q15 and Announced Divestitures

August 21, 2015 9:56 AM EDT

Wedbush maintained a Neutral rating on Intuit (NASDAQ: INTU), and cut the price target to $96.00 (from $97.00), following the company's 4Q15 earnings results. Revenue of $754 million topped consensus of $739 million. Non-GAAP EPS of $(0.06) topped consensus of $(0.11). Company issued FY16 revenue growth of $4.525-$4.6 billion, below... More

First Analysis Downgrades Intuit (INTU) to Underweight

August 21, 2015 6:39 AM EDT

First Analysis downgraded Intuit (NASDAQ: INTU) from Equal Weight to Underweight.

For an analyst ratings summary and ratings history on Intuit click here. For more ratings news on Intuit click here.

Shares of Intuit closed at $102.93 yesterday.

... More

After Hours Stocks Movers 08/20: (ARAY) (BRCD) (CRM) HIGHER; (TFM) (ROST) (NDSN) (HPQ) LOWER (more...)

August 20, 2015 5:37 PM EDT

The Fresh Market (NASDAQ: TFM) 11% LOWER; reported Q2 EPS of $0.36, $0.04 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $442.1 million versus the consensus estimate of $458.34 million. Comparable store sales decreased 1.0%. The Fresh Market sees FY2015 EPS of $1.55-$1.65, versus the consensus of $1.85.

Ross Stores (NASDAQ: ROST) 9.5% LOWER; reported Q2 EPS of $0.63, $0.01 better than the analyst estimate of $0.62. Sales for the fiscal 2015 second quarter rose 9% to $2.968 billion, with comparable store sales up 4% over the... More

Market Wrap: Existing Sales Outpace in July; Valeant Moves on Sprout Pharma; Trian Welcomed to Sysco's Board

August 20, 2015 5:21 PM EDT

Market wrap for August 20th

End of the Day: S&P 500 down 43.9 to 2,035.73; Dow Jones down 358.0 to 16,990.69; Nasdaq down 141.6 to 4,877.49

Market Brief: U.S. markets sank Thursday as investors continued taking profits.

Initial unemployment claims showed a surprise gain last week.

Valeant moved to acquire Sprout Pharma, which received approval this week from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for flibanserin, which will be marketed as Addyi in the U.S. Addyi has... More

Intuit (INTU) Tops Q4 EPS by 7c; Issues Light Q1, FY16 Outlook

August 20, 2015 4:01 PM EDT

Intuit (NASDAQ: INTU) reported Q4 EPS of ($0.05), $0.07 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $696 million versus the consensus estimate of $738.98 million.

Intuit sees FY2016 EPS of $3.40-$3.45, versus the consensus of $3.82. Intuit sees FY2016 revenue of $4.525-4.600... More

Trading Radar for 8/20: HP (HPQ), salesforce.com (CRM), Sears (SHLD), JinkoSolar (JKS), Intuit (INTU) Report

August 19, 2015 2:40 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Initial Claims - Street sees 272kContinuing Claims - Street sees 2.265M

Earnings:

58.com (NYSE: WUBA) - consensus loss $0.46
Abeona Therapeutics (Nasdaq: ABEO) - no Street consensus
American Woodmark (Nasdaq: AMWD) - consensus EPS $0.70
BioLineRx (Nasdaq: BLRX) - consensus loss $0.08
Bon-Ton Stores (Nasdaq:... More

Deutsche Bank Upgrades Intuit (INTU) to Buy

August 19, 2015 6:44 AM EDT

Deutsche Bank upgraded Intuit (NASDAQ: INTU) from Hold to Buy with a price target of $120.00 (from $100.00). Analyst Nandan Amladi thinks QBO momentum will continue.

"Intuit reports F4Q15 results on Aug 20 and will host its annual analyst day on September 18 at the... More